Western Standard LLC acquired a new stake in Avantor, Inc. (NYSE:AVTR – Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 2,109,984 shares of the company’s stock, valued at approximately $20,889,000. Avantor accounts for about 7.1% of Western Standard LLC’s holdings, making the stock its 5th biggest position. Western Standard LLC owned about 0.31% of Avantor at the end of the most recent reporting period.
Other large investors have also bought and sold shares of the company. EverSource Wealth Advisors LLC raised its position in Avantor by 119.1% in the second quarter. EverSource Wealth Advisors LLC now owns 2,187 shares of the company’s stock worth $29,000 after acquiring an additional 1,189 shares in the last quarter. Private Trust Co. NA boosted its position in shares of Avantor by 46.2% during the 4th quarter. Private Trust Co. NA now owns 2,769 shares of the company’s stock valued at $32,000 after purchasing an additional 875 shares in the last quarter. Strategic Wealth Investment Group LLC bought a new position in shares of Avantor during the 2nd quarter valued at about $32,000. Los Angeles Capital Management LLC acquired a new position in shares of Avantor in the 4th quarter worth approximately $32,000. Finally, Osaic Holdings Inc. grew its stake in shares of Avantor by 60.9% in the 2nd quarter. Osaic Holdings Inc. now owns 2,810 shares of the company’s stock worth $38,000 after purchasing an additional 1,064 shares during the last quarter. Institutional investors own 95.08% of the company’s stock.
Wall Street Analyst Weigh In
Several research firms recently commented on AVTR. Royal Bank Of Canada increased their target price on shares of Avantor from $9.00 to $14.00 and gave the company a “sector perform” rating in a research note on Thursday, July 30th. Morgan Stanley lifted their price target on shares of Avantor from $10.00 to $14.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 30th. TD Cowen reaffirmed a “hold” rating on shares of Avantor in a report on Wednesday, July 15th. Evercore set a $10.50 price objective on Avantor in a research report on Monday, July 6th. Finally, Wall Street Zen raised Avantor from a “hold” rating to a “buy” rating in a research note on Saturday, June 27th. Two research analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $12.00.
Avantor Price Performance
AVTR opened at $13.97 on Thursday. The firm has a market capitalization of $9.45 billion, a P/E ratio of -16.63, a PEG ratio of 10.04 and a beta of 0.89. The stock has a fifty day moving average of $11.44 and a 200-day moving average of $9.59. The company has a quick ratio of 1.18, a current ratio of 1.78 and a debt-to-equity ratio of 0.65. Avantor, Inc. has a 12-month low of $7.26 and a 12-month high of $15.93.
Avantor (NYSE:AVTR – Get Free Report) last issued its quarterly earnings results on Wednesday, July 29th. The company reported $0.21 earnings per share for the quarter, beating analysts’ consensus estimates of $0.19 by $0.02. The business had revenue of $1.69 billion for the quarter, compared to the consensus estimate of $1.61 billion. Avantor had a positive return on equity of 9.92% and a negative net margin of 8.81%.Avantor’s revenue for the quarter was up .5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.24 earnings per share. Avantor has set its FY 2026 guidance at 0.800-0.830 EPS. Equities analysts forecast that Avantor, Inc. will post 0.81 EPS for the current fiscal year.
About Avantor
Avantor, Inc (NYSE:AVTR) is a global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. The company delivers essential solutions that support research, development, production and safety applications. Its product portfolio spans from high-purity chemicals and reagents to biologics and cell culture media, as well as lab equipment, consumables and custom manufacturing services.
Avantor’s offerings are organized across two primary segments.
Recommended Stories
- Five stocks we like better than Avantor
- Bloom Energy’s AI Surge Meets a Valuation Reality Check
- Target Is Winning Shoppers Back—Can the Rally Reach $180?
- IonQ’s Space Contract Points to a New Frontier for Quantum Investors
- Is Apple’s AI Strategy Smarter Than Skeptics Think?
Receive News & Ratings for Avantor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avantor and related companies with MarketBeat.com's FREE daily email newsletter.
